化学療法誘発性好中球減少症の世界市場：成長、将来展望、競合分析 (2022年～2030年)

化学療法誘発性好中球減少症は、がん化学療法による非常に一般的な副作用であり、好中球減少症の病因・重症度・期間に基づいて治療されます。さまざまな形態のがんの有病率の上昇や、新規治療薬の研究開発 (R&D) 活動の拡大が、世界の化学療法誘発性好中球減少症市場の成長を後押ししています。

地域別に見ると、北米が世界有数の収益発生セグメントとなっています。一方、アジア太平洋予測期間中に最も高い成長率を示すと予想されます。

当レポートでは、世界の化学療法誘発性好中球減少症の市場について分析し、市場の基本構造やマクロ的・ミクロ的環境要因、全体的な市場規模の動向見通し (2020年～2030年)、治療法別・地域別の詳細動向、主な市場促進・抑制要因、主要企業のプロファイルと成長戦略、といった情報を取りまとめてお届けいたします。

目次

第1章 序論

第2章 エグゼクティブサマリー

第3章 化学療法誘発性好中球減少症市場：競合分析

• 化学療法誘発性好中球減少症市場：主要ベンダーの市場ポジショニング
• 化学療法誘発性好中球減少症市場のベンダーが採用した戦略
• 主要な業界戦略
• 階層分析 (2021年・2030年)

第4章 化学療法誘発性好中球減少症市場：マクロ分析と市場力学

• イントロダクション
• 世界の化学療法誘発性好中球減少症の市場規模 (単位：100万米ドル、2020年～2030年)
• 市場力学
  • 市場促進要因
  • 市場抑制要因
  • 主な課題
  • 主な機会
• 促進・抑制要因の影響分析
• シーソー分析

第5章 化学療法誘発性好中球減少症市場：治療法別 (単位：100万米ドル、2020年～2030年)

• 市場概要
• 成長・収益分析 (2021年/2030年)
• 市場区分
  • 抗生物質療法
  • コロニー刺激因子療法
  • 顆粒球輸血
  • 脾臓摘出術

第6章 北米の化学療法誘発性好中球減少症市場 (単位：100万米ドル、2020年～2030年)

• 市場概要
• 化学療法誘発性好中球減少症市場：治療法別 (単位：100万米ドル、2020年～2030年)
• 化学療法誘発性好中球減少症市場：地域別 (単位：100万米ドル、2020年～2030年)
  • 北米

第7章 英国・EU諸国の化学療法誘発性好中球減少症市場 (単位：100万米ドル、2020年～2030年)

第8章 アジア太平洋の化学療法誘発性好中球減少症市場 (単位：100万米ドル、2020年～2030年)

第9章 ラテンアメリカの化学療法誘発性好中球減少症市場 (単位：100万米ドル、2020年～2030年)

第10章 中東・アフリカの化学療法誘発性好中球減少症市場 (単位：100万米ドル、2020年～2030年)

第11章 企業プロファイル

• Amgen
• Apotex
• Baxter International
• Biogenomics Limited
• Ligand Pharmaceuticals
• Lupin Limited
• Novartis AG
• Pfizer Inc.
• Reddy's Laboratory
• Sanofi
• Teva Pharmaceuticals Industries

List of Tables

• TABLE 1 Global Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 2 North America Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 3 U.S. Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 4 Canada Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 5 Rest of North America Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 6 UK and European Union Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 7 UK Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 8 Germany Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 9 Spain Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 10 Italy Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 11 France Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 12 Rest of Europe Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 13 Asia Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 14 China Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 15 Japan Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 16 India Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 17 Australia Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 18 South Korea Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 19 Latin America Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 20 Brazil Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 21 Mexico Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 22 Rest of Latin America Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 23 Middle East and Africa Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 24 GCC Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 25 Africa Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)
• TABLE 26 Rest of Middle East and Africa Chemotherapy Induced Neutropenia Market By Treatment, 2020-2030, USD (Million)

List of Figures

• FIG. 1 Global Chemotherapy Induced Neutropenia Market: Market Coverage
• FIG. 2 Research Methodology and Data Sources
• FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
• FIG. 4 Global Chemotherapy Induced Neutropenia Market: Quality Assurance
• FIG. 5 Global Chemotherapy Induced Neutropenia Market, By Treatment, 2021
• FIG. 6 Global Chemotherapy Induced Neutropenia Market, By Geography, 2021
• FIG. 7 Market Geographical Opportunity Matrix - Global Chemotherapy Induced Neutropenia Market, 2021
• FIG. 8 Market Positioning of Key Chemotherapy Induced Neutropenia Market Players, 2021
• FIG. 9 Global Chemotherapy Induced Neutropenia Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
• FIG. 10 Global Chemotherapy Induced Neutropenia Market, By Treatment, 2021 Vs 2030, %
• FIG. 11 U.S. Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 12 Canada Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 13 Rest of North America Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 14 UK Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 15 Germany Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 16 Spain Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 17 Italy Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 18 France Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 19 Rest of Europe Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 20 China Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 21 Japan Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 22 India Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 23 Australia Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 24 South Korea Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 25 Rest of Asia Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 26 Brazil Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 27 Mexico Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 28 Rest of Latin America Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 29 GCC Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 30 Africa Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030
• FIG. 31 Rest of Middle East and Africa Chemotherapy Induced Neutropenia Market (US$ Million), 2020 - 2030

Chemotherapy-induced neutropenia is a very common side effect of cancer chemotherapy, it is treated on the basis of etiology, severity, and duration of the neutropenia. Growing prevalence of different forms of cancer and increasing research and development activities for novel therapeutics are primarily driving the growth of the chemotherapy-induced neutropenia market globally.

The report titled "Chemotherapy Induced Neutropenia Market - Growth, Future Prospects and Competitive Analysis, 2022-2030" offers strategic insights into the overall chemotherapy-induced neutropenia market along with the market size and estimates for the duration 2020 to 2030.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers for understanding the ongoing trends in the global chemotherapy-induced neutropenia market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global chemotherapy-induced neutropenia market. This report concludes with company profiles section that highlights major information about the key players engaged in global chemotherapy-induced neutropenia market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global chemotherapy-induced neutropenia market, offering market size and estimates for the period from 2020 to 2030, keeping in mind the above-mentioned factors.

Chemotherapy-induced neutropenia is a very common side effect of cancer chemotherapy, it is treated on the basis of etiology, severity, and duration of the neutropenia. Growing prevalence of different forms of cancer and increasing research and development activities for novel therapeutics are primarily driving the growth of chemotherapy-induced neutropenia market globally. However, many of these medications are not available to patients in most countries, and even when registered they may not be reimbursed under public health insurance programs which may negatively impacting the growth of chemotherapy-induced neutropenia market. There are different types of treatment available in market for chemotherapy-induced neutropenia which are given on the basis of severity, it includes antibiotic therapy, colony stimulating factor therapy, granulocyte transfusion, splenectomy procedure and other therapy. It is observed that in the base year 2021, colony stimulating factor therapy is major revenue generating segment, due to its preferable use in treatment of chemotherapy induce neutropenia as they have ability to reduce the incidence and severity of neutropenia and febrile neutropenia while improving chemotherapy dose intensity. Regulatory guidelines recommend prophylactic G-CSF treatment for chemotherapy patients with an overall high risk (≥20%) is the prime factor that driving the growth of G-CSF market globally. Currently, Neupogen (filgrastim) and Neulasta (pegfilgrastim) held largest market share approved by the regulatory bodies for treatment of chemotherapy-induced neutropenia.

Chemotherapy induced neutropenia is the dose limiting toxicity of systemic cancer chemotherapy, it is the most serious hematologic toxicity and associated with the risk of life-threatening infections, as well as chemotherapy dose reductions. It is observed that currently, North America is major revenue generating segment due to factors such as increase in prevalence of different forms of cancer, upsurge funding by the government for life-threatening diseases such as cancer, high treatment awareness, higher investment in R&D by key players and research organizations are primarily driving the market growth in North America. On the other hand Asia Pacific is expected to show fastest growth during forecast period due to factors such as rising prevalence of different form of cancer, upsurge funding by the government and private organization for treatment, key manufacturers partnership with local manufacturers and rising treatment awareness would assist market growth in Asia Pacific.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Chemotherapy Induced Neutropenia market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Chemotherapy Induced Neutropenia market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Treatment

Antibiotic Therapy

Colony Stimulating Factor Therapy

Granulocyte Transfusion

Splenectomy Procedure

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Chemotherapy Induced Neutropenia market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Chemotherapy Induced Neutropenia market?

Which is the largest regional market for Chemotherapy Induced Neutropenia market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Chemotherapy Induced Neutropenia market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Chemotherapy Induced Neutropenia market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Chemotherapy Induced Neutropenia Market
• 2.2. Global Chemotherapy Induced Neutropenia Market, By Treatment, 2021 (US$ Million)
• 2.3. Global Chemotherapy Induced Neutropenia Market, By Geography, 2021 (US$ Million)
• 2.4. Attractive Investment Proposition by Geography, 2021

3. Chemotherapy Induced Neutropenia Market: Competitive Analysis

• 3.1. Market Positioning of Key Chemotherapy Induced Neutropenia Market Vendors
• 3.2. Strategies Adopted by Chemotherapy Induced Neutropenia Market Vendors
• 3.3. Key Industry Strategies
• 3.4. Tier Analysis 2021 Versus 2030

4. Chemotherapy Induced Neutropenia Market: Macro Analysis & Market Dynamics

• 4.1. Introduction
• 4.2. Global Chemotherapy Induced Neutropenia Market Value, 2020 - 2030, (US$ Million)
• 4.3. Market Dynamics
  • 4.3.1. Market Drivers
  • 4.3.2. Market Restraints
  • 4.3.3. Key Challenges
  • 4.3.4. Key Opportunities
• 4.4. Impact Analysis of Drivers and Restraints
• 4.5. See-Saw Analysis

5. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2021 Versus 2030
• 5.3. Market Segmentation
  • 5.3.1. Antibiotic Therapy
  • 5.3.2. Colony Stimulating Factor Therapy
  • 5.3.3. Granulocyte Transfusion
  • 5.3.4. Splenectomy Procedure

6. North America Chemotherapy Induced Neutropenia Market, 2020-2030, USD (Million)

• 6.1. Market Overview
• 6.2. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
• 6.3.Chemotherapy Induced Neutropenia Market: By Region, 2020-2030, USD (Million)
  • 6.3.1.North America
    • 6.3.1.1. U.S.
      • 6.3.1.1.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
    • 6.3.1.2. Canada
      • 6.3.1.2.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
    • 6.3.1.3. Rest of North America
      • 6.3.1.3.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)

7. UK and European Union Chemotherapy Induced Neutropenia Market, 2020-2030, USD (Million)

• 7.1. Market Overview
• 7.2. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
• 7.3.Chemotherapy Induced Neutropenia Market: By Region, 2020-2030, USD (Million)
  • 7.3.1.UK and European Union
    • 7.3.1.1. UK
      • 7.3.1.1.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
    • 7.3.1.2. Germany
      • 7.3.1.2.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
    • 7.3.1.3. Spain
      • 7.3.1.3.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
    • 7.3.1.4. Italy
      • 7.3.1.4.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
    • 7.3.1.5. France
      • 7.3.1.5.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
    • 7.3.1.6. Rest of Europe
      • 7.3.1.6.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)

8. Asia Pacific Chemotherapy Induced Neutropenia Market, 2020-2030, USD (Million)

• 8.1. Market Overview
• 8.2. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
• 8.3.Chemotherapy Induced Neutropenia Market: By Region, 2020-2030, USD (Million)
  • 8.3.1.Asia Pacific
    • 8.3.1.1. China
      • 8.3.1.1.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
    • 8.3.1.2. Japan
      • 8.3.1.2.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
    • 8.3.1.3. India
      • 8.3.1.3.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
    • 8.3.1.4. Australia
      • 8.3.1.4.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
    • 8.3.1.5. South Korea
      • 8.3.1.5.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
    • 8.3.1.6. Rest of Asia Pacific
      • 8.3.1.6.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)

9. Latin America Chemotherapy Induced Neutropenia Market, 2020-2030, USD (Million)

• 9.1. Market Overview
• 9.2. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
• 9.3.Chemotherapy Induced Neutropenia Market: By Region, 2020-2030, USD (Million)
  • 9.3.1.Latin America
    • 9.3.1.1. Brazil
      • 9.3.1.1.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
    • 9.3.1.2. Mexico
      • 9.3.1.2.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
    • 9.3.1.3. Rest of Latin America
      • 9.3.1.3.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)

10. Middle East and Africa Chemotherapy Induced Neutropenia Market, 2020-2030, USD (Million)

• 10.1. Market Overview
• 10.2. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
• 10.3.Chemotherapy Induced Neutropenia Market: By Region, 2020-2030, USD (Million)
  • 10.3.1.Middle East and Africa
    • 10.3.1.1. GCC
      • 10.3.1.1.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
    • 10.3.1.2. Africa
      • 10.3.1.2.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)
    • 10.3.1.3. Rest of Middle East and Africa
      • 10.3.1.3.1. Chemotherapy Induced Neutropenia Market: By Treatment, 2020-2030, USD (Million)

11. Company Profile

• 11.1. Amgen
  • 11.1.1. Company Overview
  • 11.1.2. Financial Performance
  • 11.1.3. Product Portfolio
  • 11.1.4. Strategic Initiatives
• 11.2. Apotex
  • 11.2.1. Company Overview
  • 11.2.2. Financial Performance
  • 11.2.3. Product Portfolio
  • 11.2.4. Strategic Initiatives
• 11.3. Baxter International
  • 11.3.1. Company Overview
  • 11.3.2. Financial Performance
  • 11.3.3. Product Portfolio
  • 11.3.4. Strategic Initiatives
• 11.4. Biogenomics Limited
  • 11.4.1. Company Overview
  • 11.4.2. Financial Performance
  • 11.4.3. Product Portfolio
  • 11.4.4. Strategic Initiatives
• 11.5. Ligand Pharmaceuticals
  • 11.5.1. Company Overview
  • 11.5.2. Financial Performance
  • 11.5.3. Product Portfolio
  • 11.5.4. Strategic Initiatives
• 11.6. Lupin Limited
  • 11.6.1. Company Overview
  • 11.6.2. Financial Performance
  • 11.6.3. Product Portfolio
  • 11.6.4. Strategic Initiatives
• 11.7. Novartis AG
  • 11.7.1. Company Overview
  • 11.7.2. Financial Performance
  • 11.7.3. Product Portfolio
  • 11.7.4. Strategic Initiatives
• 11.8. Pfizer Inc.
  • 11.8.1. Company Overview
  • 11.8.2. Financial Performance
  • 11.8.3. Product Portfolio
  • 11.8.4. Strategic Initiatives
• 11.9. Reddy's Laboratory
  • 11.9.1. Company Overview
  • 11.9.2. Financial Performance
  • 11.9.3. Product Portfolio
  • 11.9.4. Strategic Initiatives
• 11.10. Sanofi
  • 11.10.1. Company Overview
  • 11.10.2. Financial Performance
  • 11.10.3. Product Portfolio
  • 11.10.4. Strategic Initiatives
• 11.11. Teva Pharmaceuticals Industries
  • 11.11.1. Company Overview
  • 11.11.2. Financial Performance
  • 11.11.3. Product Portfolio
  • 11.11.4. Strategic Initiatives